MedTrace Logo

A Novel Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplant in Patients Aged ≥ 40 Years Old With Severe Aplastic Anemia

NCT07586735 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2026-05-14

No results posted yet for this study

Summary

The goal of this prospective, multicenter, single arm observational study is to evaluate the efficacy and safety of the BFCA regimen in ≥ 40 years old SAA patients undergoing haplo-HSCT.

Conditions

  • Busulfan 0.8 mg/kg/q6h (Days -8 to -7) Fludarabine 30mg/m2/Day (Days -6 to -2) Cyclophosphamide 25 mg/kg/Day and r-ATG 2.5 mg/kg/Day (Days -5 to -2)

Interventions

OTHER

BFC conditiong regimen

Conditioning regimens include 0.8 mg/kg/6h busulfan (days -8 to -7), 30mg/m2/day fludarabine (days -6 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2).

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2026-12-31
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07586735 on ClinicalTrials.gov